NewsBenzingaReported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Benzinga 2026.11.17 06:29 (GMT+0) Open on Benzinga Other news Is Wall Street Bullish or Bearish on Zimmer Biomet Stock? Clorox Stock Outlook: Is Wall Street Bullish or Bearish? Shorting ConocoPhillips Puts and Put Credit Spreads Are Attractive Income Plays Trump Administration Shrugs Off Big Tech Warnings, Advances Plan to Restrict Chinese Data Center Gear Despite Compliance Woes: Report How To Earn $500 A Month From Target Stock Ahead Of Q3 Earnings Stifel Reinstates Buy on Walmart, Announces $145 Price Target
Trump Administration Shrugs Off Big Tech Warnings, Advances Plan to Restrict Chinese Data Center Gear Despite Compliance Woes: Report